Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
34 hedge funds and large institutions have $7.9M invested in Lumos Pharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
7% more capital invested
Capital invested by funds: $7.4M → $7.9M (+$494K)
6% less funds holding
Funds holding: 36 → 34 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
+$543K |
| 2 |
LPC
Lion Point Capital
New York
|
+$95.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$70.7K |
| 4 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
+$67K |
| 5 |
Renaissance Technologies
New York
|
+$4.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$68.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$52.7K |
| 3 |
BlackRock
New York
|
-$38.4K |
| 4 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
-$26.3K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$21.2K |
LUMO Hedge Fund Activity: Q2 2023 in Review
34 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2023, worth a combined $7.9M — up 6.7% from $7.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LUMO and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Acuitas Investments, opening a new position worth an estimated $543K. The largest seller was Millennium Management, cutting an estimated $68.5K.
- 34 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2023, down from 36 in Q1 2023.
- Funds reported $7.9M of Lumos Pharma, Inc. Common Stock stock for Q2 2023, up 6.7% quarter-over-quarter.
- 1 fund opened new Lumos Pharma, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2023 was Acuitas Investments, an estimated $543K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2023 was Millennium Management, an estimated $68.5K sold.
Based on aggregated 13F filings for Q2 2023.